Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

"Competing interests: MJ received support for attending meetings and/or travel from Roche and Takeda; participation on a Data Safety Monitoring Board or Advisory Board for Novartis, Innomedica, Debiopharm, AstraZeneca and BMS. EC is employed by START and HM Hospitales Group and holds a leadership role at START, Pharma Mar, EORTC, Sanofi, BeiGene, Novartis and Merus NV; is a stockholder of START and Oncoart Associate, received grants from START, received consulting fees or honoraria from Nanobiotix, Janssen-Cilag, Roche/Genentech, TargImmune Therapeutics, Servier, Bristol-Myers Squibb, Amunix, Adcendo, Anaveon, AstraZeneca/MedImmune, Chugai Pharma, MonTa, MSD Oncology, Nouscom, Novartis, OncoDNA, T-Knife, Elevation Oncology, PharmaMar, Ellipses Pharma, Syneos Health, Genmab, Diaccurate and HM Hospitales Group. HL received consulting fees from BMS, Palleon, MSD; support for attending meetings and/or travel from Amgen. JL received consulting fees for participation in an Advisory Board for Roche Genentech, GSK, Basilea and Pierre-Faber. ECdlF, GA, VSP and DH have no disclosures. DK received consulting fees from AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen and Sanofi; support for attending meetings and/or travel from Amgen, Roche and Sanofi; participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca, Merck, MSD. CB and SJ were employees and held stock options of Anaveon AG during the conduct of this study. EG received grants/contracts from Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene, Janssen; consulting fees from Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Thermo Fisher, MabDiscovery, Anaveon, F-Star Therapeutics, Hengrui, Sanofi, Incyte; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Merck Sharp & Dohme, Roche, Thermo Fisher, Lilly, Novartis, SeaGen; Principal Investigator or Insitutional Co-for studies sponsored by: Adaptimmune LLC, Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Bicycletx Ltd, BioInvent International AB, Biontech SE, Biontech Small Molecules Gmbh, Boehringer Ingelhem International Gmbh, Catalym Gmbh, Cyclacel Biopharmaceuticals, Cytovation AS, Cytomx, F.Hoffmann La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hifibio Therapeutics, Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Incyte Corporation, Incyte Europe Sàrl, Janssen-Cilag International NV, Janssen-Cilag SA, Laboratorios Servier SL, Medimmune Llc, Merck & Co, Inc, Merck Kgga, Novartis Farmacéutica, S.A, Peptomyc, Pfizer Slu, Relay Therapeutics, Replimmune, Ribon Therapeutics, Ryvu Therapeutics SA, Seattle Genetics Inc, Sotio as, Sqz Biotechnologies, Symphogen A/S, Taiho Pharma Usa Inc and T-Knife Gmbh."

"Funding: This study was funded by Anaveon AG, Basel, Switzerland."

"Trial registration number NCT04855929."